Search

Your search keyword '"lactacystin"' showing total 1,494 results

Search Constraints

Start Over You searched for: Descriptor "lactacystin" Remove constraint Descriptor: "lactacystin"
1,494 results on '"lactacystin"'

Search Results

1. Intranasal Administration of GRP78 Protein (HSPA5) Confers Neuroprotection in a Lactacystin-Induced Rat Model of Parkinson's Disease.

2. Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin-aldosterone system

3. Lactacystin-induced kidney fibrosis: Protection by melatonin and captopril.

4. Lactacystin-induced kidney fibrosis: Protection by melatonin and captopril

5. Modulation of the Ubiquitin-Proteasome System Restores Plasticity in Hippocampal Pyramidal Neurons of the APP/PS1 Alzheimer's Disease-Like Mice.

6. Lack of Parkinsonian Pathology and Neurodegeneration in Mice After Long-Term Injections of a Proteasome Inhibitor in Olfactory Bulb and Amygdala.

7. The Chaperone Inducer U133 Eliminates Anhedonia and Prevents Neurodegeneration in Monoaminergic Emotiogenic Brain Structures in a Preclinical Model of Parkinson's Disease in Aged Rats.

8. Lack of Parkinsonian Pathology and Neurodegeneration in Mice After Long-Term Injections of a Proteasome Inhibitor in Olfactory Bulb and Amygdala

9. Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin-aldosterone system.

10. Impairment to Cognitive Functions in Wistar Rats in a Model of the Preclinical Stage of Parkinson's Disease.

11. Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson's disease.

12. Assessment of the Neuroprotective Potential of Glucose-Regulated Heat Shock Protein in a Model of Parkinson's Disease in Rats.

13. Age-Related Features of α-Synuclein Pathology in the Brain on Modeling the Preclinical Stage of Parkinson's Disease in Rats.

15. How does conserved dopamine neurotrophic factor protect against and rescue neurodegeneration of PC12 cells?

16. Systemic LPS-induced neuroinflammation increases the susceptibility for proteasome inhibition-induced degeneration of the nigrostriatal pathway.

17. An Infection Hypothesis of Parkinson's Disease.

18. The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease.

19. A new reporter cell line for studies with proteasome inhibitors in Trypanosoma brucei.

20. Ketamine Does Not Exert Protective Properties on Dopaminergic Neurons in the Lactacystin Mouse Model of Parkinson’s Disease

21. The Chaperone Inducer U133 Eliminates Anhedonia and Prevents Neurodegeneration in Monoaminergic Emotiogenic Brain Structures in a Preclinical Model of Parkinson’s Disease in Aged Rats

23. Fewer adverse effects associated with a modified two-bag intravenous acetylcysteine protocol compared to traditional three-bag regimen in paracetamol overdose.

24. The Protective Effect of Repeated 1MeTIQ Administration on the Lactacystin-Induced Impairment of Dopamine Release and Decline in TH Level in the Rat Brain.

25. Study of Age-Related Changes in Compensatory Processes in the Model of Neurodegeneration of the Nigrostriatal System in Rats.

26. Ketamine Does Not Exert Protective Properties on Dopaminergic Neurons in the Lactacystin Mouse Model of Parkinson's Disease.

27. Normal glutathione levels in autopsied brain of chronic users of heroin and of cocaine.

28. New HSF1 inducer as a therapeutic agent in a rodent model of Parkinson's disease.

29. Temporal-Spatial Profiling of Pedunculopontine Galanin-Cholinergic Neurons in the Lactacystin Rat Model of Parkinson’s Disease.

30. S100A16 up‑regulates Oct4 and Nanog expression in cancer stem‑like cells of Yumoto human cervical carcinoma cells.

31. Nigrostriatal proteasome inhibition impairs dopamine neurotransmission and motor function in minipigs.

32. Protein kinase C-eta regulates Mcl-1 level via ERK1.

34. Age-Related Characteristics of Sleep Impairments in a Model of the Preclinical Stage of Parkinson’s Disease in Rats

35. Assessment of the Efficacy of Preventive Therapy with Chaperone Inducer U133 in a Model of the Preclinical Stage of Parkinson’s Disease in Elderly Rats

38. Effects of Quercetin on Neurodegenerative and Compensatory Processes in the Nigrostriatal System in a Model of the Preclinical Stage of Parkinson's Disease in Rats.

39. Early Use of N-acetylcysteine With Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment--Elevation Myocardial Infarction Reduces Myocardial Infarct Size (the NACIAM Trial [N-acetylcysteine in Acute Myocardial Infarction]).

40. Aβ42-mediated proteasome inhibition and associated tau pathology in hippocampus are governed by a lysosomal response involving cathepsin B: Evidence for protective crosstalk between protein clearance pathways.

41. Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril.

42. Glutamine promotes Hsp70 and inhibits α-Synuclein accumulation in pheochromocytoma PC12 cells.

43. [18F]FP-(+)-DTBZ PET study in a lactacystin-treated rat model of Parkinson disease.

44. N-acetylcysteine a possible protector against indomethacin-induced peptic ulcer: crosstalk between antioxidant, anti-inflammatory, and antiapoptotic mechanisms.

45. Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system xc−.

46. Plastic changes at corticostriatal synapses predict improved motor function in a partial lesion model of Parkinson’s disease.

47. Caloric Restriction Protects against Lactacystin-Induced Degeneration of Dopamine Neurons Independent of the Ghrelin Receptor.

48. The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA.

49. The Proteasome Inhibition Model of Parkinson's Disease.

50. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.

Catalog

Books, media, physical & digital resources